Lupin launches generic Mirabegron extended-release tablets (25 mg) in the US market, approved by USFDA. The drug treats overactive bladder.
New Delhi, Apr 22 (PTI) Drug maker Lupin on Monday said it has launched Mirabegron extended-release tablets (25 mg) in the US market.
The Mumbai-based drug maker has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is a generic equivalent of Astellas Pharma Global Development, Inc's Myrbetriq extended-release tablets, it added.
Mirabegron extended-release tablets are used to treat certain bladder problems including overactive bladder.
Lupin shares were trading 3.38 per cent up at Rs 1,599.35 apiece on the BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback